Skip to main content
. 2018 Jan 8;9(2):95–107. doi: 10.1007/s12672-017-0319-0

Fig. 3.

Fig. 3

Collective evidence indicates that adjuvant therapy with currently used GR agonists have both a beneficial and deleterious impact on concurrent chemotherapy treatment. These opposing activities may balance each other to mask an impact on overall or progression-free survival, resulting in clinical studies concluding that adjuvant glucocorticoids do not negatively impact the patient